866-997-4948(US-Canada Toll Free)

Atrial Fibrillation Therapeutics Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Dec 2010

Category :

Therapeutic Area

No. of Pages : 42 Pages


GlobalData, the industry analysis specialist, has released a new report, “Atrial Fibrillation Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global atrial fibrillation therapeutics. The report identifies the key trends shaping and driving the global atrial fibrillation therapeutics. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. 

Most importantly, the report provides valuable insights on the pipeline products within the global atrial fibrillation therapeutics. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis shows that the atrial fibrillation therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 4.5%, from $518m in 2001 to $795m in 2009. The market is predicted to grow at an astounding CAGR of 23.5% from 2009 and reach a total value of $4.2 billion by 2017. A high projected growth rate is chiefly attributed to the potentially strong late-stage pipeline. The availability of new first-in-class therapies with better safety and efficacy profiles is therefore expected to drive the growth of the atrial fibrillation therapeutics market in the next few years. 

Scope

The report provides information on the key drivers and challenges in the atrial fibrillation therapeutics market. Its scope includes:

  • Annualized global atrial fibrillation therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • The pipeline assessment shows that the atrial fibrillation pipeline is strong and the developmental pipeline consists of 26 first-in-class molecules, such as Azimilide from Warner Chilcott and Xarelto from Bayer. Some of the molecules in Phase II are Celivarone from Sanofi-Aventis and Tecadenoson from Gilead Life Sciences.
  • Analysis of the current and future market competition in the global atrial fibrillation therapeutics market. The key market players operating in this market are Pfizer, Sanofi Aventis, Bayer Healthcare, Berlex Laboratories, Boehringer Ingelheim, Merck & Co, Warner Chilcott, Daiichi Sankyo Co and others
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the atrial fibrillation therapeutics market
Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global atrial fibrillation therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global atrial fibrillation therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global atrial fibrillation therapeutics market landscape? - Identify, understand and capitalize.
Table of Content

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Atrial Fibrillation Therapeutics: Introduction 6
2.1 Overview 6
2.2 GlobalData Pipeline Report Guidance 6

3 Atrial Fibrillation Therapeutics: Market Characterization 7
3.1 Atrial Fibrillation Market Size 7
3.2 Atrial Fibrillation Market Forecast and CAGR 8
3.3 Drivers and Barriers for the Atrial Fibrillation Therapeutics Market 9
3.3.1 Drivers of the Atrial Fibrillation Therapeutics Market 9
3.3.2 Barriers for the Atrial Fibrillation Therapeutics Market 10
3.4 Opportunity and Unmet Need 10
3.5 Key Takeaway 11

4 Atrial Fibrillation Therapeutics Market: Competitive Assessment 12
4.1 Overview 12
4.2 Strategic Competitor Assessment 12
4.3 Product Profile for the Major Marketed Products in the Atrial Fibrillation Therapeutics Market 13
4.3.1 Multaq (Dronedarone) 13
4.3.2 Tikosyn (dofetilide) 14
4.3.3 Tambocor (Flecainide acetate) 15
4.3.4 Coumadin (Warfarin - Anticoagulants) 16
4.3.5 Betapace AF 17
4.3.6 Pradaxa (Dabigatran Etexilate) 17
4.4 Key Takeaway 19

5 Atrial Fibrillation Therapeutics: Pipeline Assessment 20
5.1 Overview 20
5.2 Strategic Pipeline Assessment 20
5.2.1 Technology Trends Analytic Framework 20
5.3 Atrial Fibrillation Therapeutics - Promising Drugs under Clinical Development 21
5.4 Drugs under Clinical Development 21
5.4.1 Xarelto (Bayer Healthcare/Johnson & Johnson) 21
5.4.2 Azimilide Dihydrochloride (Stedicor) (Warner Chilcott/Blue Ash Therapeutics) 22
5.4.3 Vernakalant oral (Merck/Cardiome Pharma) 23
5.4.4 Edoxaban 24
5.5 Atrial Fibrillation Therapeutics Market - Clinical Pipeline by Mechanism of Action 25
5.6 Atrial Fibrillation Pipeline - Pipeline by Clinical Phases of Development 25
5.6.1 Atrial Fibrillation Therapeutics - Phase III Clinical Pipeline 26
5.6.2 Atrial Fibrillation Therapeutics - Phase II Clinical Pipeline 26
5.6.3 Atrial Fibrillation Therapeutics - Phase I Clinical Pipeline 26
5.6.4 Atrial Fibrillation Therapeutics - Preclinical Pipeline 27
5.7 Key Takeaway 27

6 Atrial Fibrillation Therapeutics: Implications for Future Market Competition 28

7 Atrial Fibrillation Therapeutics: Future Players in the Atrial Fibrillation Market 29

7.1 Introduction 29
7.2 Cardiome Pharma and Astellas Pharma 29
7.2.1 Overview 29
7.2.2 Business Description 29
7.2.3 CV Portfolio 30
7.3 Sanofi Aventis 30
7.3.1 Overview 30
7.3.2 Business Description 31
7.3.3 CV Portfolio 31
7.4 Daiichi Sankyo Company 32
7.4.1 Overview 32
7.4.2 Business Description 32
7.4.3 CV Portfolio 33
7.4.4 Atrial Fibrillation product portfolio 33
7.5 Bayer Healthcare 34
7.5.1 Overview 34
7.5.2 Business Description 34
7.5.3 CV Portfolio 34
7.5.4 Atrial Fibrillation Product Portfolio 35

8 Atrial Fibrillation Therapeutics Market: Appendix 36
8.1 Definitions 36
8.2 Acronyms 36
8.3 Research Methodology 37
8.3.1 Coverage 37
8.3.2 Secondary Research 37
8.3.3 Forecasting 38
8.3.4 Primary Research 41
8.3.5 Expert Panel Validation 41
8.4 Contact Us 41
8.5 Disclaimer 41
8.6 Sources 42

List of Table


Table 1: Atrial Fibrillation Therapeutics, Global, Market Revenue ($m), 2001-2009 7
Table 2: Atrial Fibrillation Therapeutics, Global, Market Forecast ($m), 2009-2017 8
Table 3: Strategic Competitor Assessment of the Major Marketed Products in Atrial Fibrillation 12
Table 4: Summary of Key Phase III Clinical Trials for Multaq 14
Table 5: Major Marketed Products for Atrial Fibrillation 18
Table 6: Atrial Fibrillation Therapeutics - Promising Drugs Under Clinical Development 21
Table 7: Clinical Study Details on ROCKET-AF with Xarelto 22
Table 8: Atrial Fibrillation Therapeutics - Phase III Clinical Pipeline 26
Table 9: Atrial Fibrillation Therapeutics - Phase II Clinical Pipeline 26
Table 10: Atrial Fibrillation Therapeutics - Phase I Clinical Pipeline 26
Table 11: Atrial Fibrillation Therapeutics - Preclinical Pipeline 27
Table 12: Cardiome and Astellas Pharma Inc. - CV and Atrial Fibrillation Pipeline 30
Table 13: Sanofi-Aventis - CV and Atrial Fibrillation Pipeline 31
Table 14: Daiichi Sankyo Co. Ltd - CV and Atrial Fibrillation Pipeline 33
Table 15: Bayer HealthCare - CV and Atrial Fibrillation Pipeline 34
Table 16: Clinical study details on ROCKET-AF with Xarelto 35

List of Chart


Figure 1: Atrial Fibrillation Therapeutics, Global, Market Revenue ($m), 2001-2009 7
Figure 2: Atrial Fibrillation Therapeutics, Global, Market Forecast ($m), 2009-2017 8
Figure 4: Technology Trends Analytic Framework of the Atrial Fibrillation Pipeline 20
Figure 5: Technology Trends Analytic Framework of Atrial Fibrillation Pipeline - Description 21
Figure 6: Atrial Fibrillation Therapeutics - Pipeline by Mechanism of Action 25
Figure 7: Atrial Fibrillation Therapeutics - Pipeline by Phases of Clinical Development 25
Figure 8: Implications for Future Market Competition in the Atrial Fibrillation Market 28
Figure 9: Atrial Fibrillation Therapeutics Market - Pipeline by Company 29
Figure 11: GlobalData Market Forecasting Model 40

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *